|
US5629178A
(en)
*
|
1994-10-28 |
1997-05-13 |
Genetics & Ivf Institute |
Method for enhancing amplification in the polymerase chain reaction employing peptide nucleic acid (PNA)
|
|
AU693023B2
(en)
*
|
1995-05-05 |
1998-06-18 |
Applied Biosystems, Llc |
Methods and reagents for combined PCR amplification and hybridization probing assay
|
|
US5939262A
(en)
*
|
1996-07-03 |
1999-08-17 |
Ambion, Inc. |
Ribonuclease resistant RNA preparation and utilization
|
|
US5677124A
(en)
*
|
1996-07-03 |
1997-10-14 |
Ambion, Inc. |
Ribonuclease resistant viral RNA standards
|
|
US6617422B1
(en)
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
|
US6485901B1
(en)
|
1997-10-27 |
2002-11-26 |
Boston Probes, Inc. |
Methods, kits and compositions pertaining to linear beacons
|
|
JP2003530817A
(ja)
|
1999-06-01 |
2003-10-21 |
ベイラー カレッジ オブ メディスン |
聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
|
|
AU2001229576A1
(en)
*
|
2000-01-15 |
2001-07-24 |
Genelabs Technologies, Inc. |
Nucleic acid binding site assay and selection method
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
ATE556714T1
(de)
|
2002-02-01 |
2012-05-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
US20030211483A1
(en)
*
|
2002-05-09 |
2003-11-13 |
Schroeder Benjamin G. |
Methods for the enrichment of low-abundance polynucleotides
|
|
KR20120002613A
(ko)
|
2002-08-12 |
2012-01-06 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
|
CA2581086C
(en)
|
2004-09-14 |
2023-11-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for treatment with bucindolol based on genetic targeting
|
|
US7964413B2
(en)
|
2005-03-10 |
2011-06-21 |
Gen-Probe Incorporated |
Method for continuous mode processing of multiple reaction receptacles in a real-time amplification assay
|
|
KR101772375B1
(ko)
*
|
2005-09-07 |
2017-08-29 |
신라젠(주) |
Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
DE602007006478D1
(de)
|
2006-05-12 |
2010-06-24 |
Cepheid Sunnyvale |
Erkennung der verbindung einer dna-rekombination
|
|
WO2009016433A2
(en)
|
2006-09-15 |
2009-02-05 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
|
US20100129902A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Erhard Ralf Schoenbrunner |
Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
|
|
US9587270B2
(en)
|
2009-06-29 |
2017-03-07 |
Luminex Corporation |
Chimeric primers with hairpin conformations and methods of using same
|
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
|
WO2011070440A2
(en)
|
2009-12-10 |
2011-06-16 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
|
ES2587191T3
(es)
|
2009-12-23 |
2016-10-21 |
Arca Biopharma, Inc. |
Métodos y composiciones para enfermedades y afecciones cardiovasculares
|
|
AU2012204467B2
(en)
|
2011-01-04 |
2016-08-18 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
EP2681566A2
(en)
|
2011-02-28 |
2014-01-08 |
University of Iowa Research Foundation |
Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender
|
|
AU2012226530B2
(en)
|
2011-03-08 |
2016-12-01 |
King Abdullah University Of Science And Technology |
Molecular biomarker set for early detection of ovarian cancer
|
|
EP2718427B1
(en)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
|
WO2013036799A2
(en)
|
2011-09-09 |
2013-03-14 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving nkg2d inhibitors and cancer
|
|
US10125373B2
(en)
|
2013-01-22 |
2018-11-13 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
|
JP2016513115A
(ja)
|
2013-02-21 |
2016-05-12 |
チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド |
ワクチン組成物
|
|
MX2016004283A
(es)
|
2013-10-03 |
2016-10-12 |
Oklahoma Med Res Found |
Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico.
|
|
BR112016016130A2
(pt)
|
2014-01-10 |
2017-08-08 |
Glaxosmithkline Ip No 2 Ltd |
Compostos e métodos
|
|
GB201411567D0
(en)
*
|
2014-06-30 |
2014-08-13 |
Epistem Ltd |
Quantification methods
|
|
CA2969145A1
(en)
|
2014-11-26 |
2016-06-02 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
AU2018213315A1
(en)
|
2017-01-26 |
2019-07-25 |
Oklahoma Medical Research Foundation |
Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
|
|
US12140592B2
(en)
|
2017-06-16 |
2024-11-12 |
Oklahoma Medical Research Foundation |
Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
|
|
US20210349088A1
(en)
|
2018-10-18 |
2021-11-11 |
Oklahoma Medical Research Foundation |
Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease Activity
|
|
US12510539B2
(en)
|
2018-10-18 |
2025-12-30 |
Progentec Diagnostics, Inc. |
Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
|
|
CN113614535B
(zh)
|
2018-10-31 |
2024-08-16 |
亚利桑那大学评议会 |
用于辐射诱导的肺损伤的生物标志物和使用方法
|
|
US20220296622A1
(en)
|
2019-09-16 |
2022-09-22 |
The Children's Hospital Of Philadelphia |
Compositions and methods for the treatment of swi-snf mutant tumors
|